Clinical trials: Confusion
Lymphoma
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter…
- Trial name
- NCT03098589
- Testing
- Revlimid
- Where
- Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Disorientation, Cognitive Impairment
Evaluation of Safe Use of SECURIDRAP® SELFIA®
Interventional, multicenter, prospective and non-comparative clinical investigation carried out in 9 French establishments in order to assess the safety of the SÉCURIDRAP® SELFIA® bedding by mesasuring all the adverse events…
- Conditions
- Disorientation, Cognitive Impairment, Behavior Disorders
- Trial name
- SECURIDRAP (NCT05510401)
- Testing
- SECURIDRAP® SELFIA®
- Where
- 10 sites in France
- Volunteers
- 108 people
- Sponsor
- Groupe Mulliez-Flory
Post-Operative Confusion
Braindex Cerebral Tissue Oxygen Saturation (SctO2) Measurement Algorithm Assessment and Improvement
The objective of this clinical trial is to optimize Braindex brain tissue oxygen saturation (SctO2) measurement algorithm compared to a mixed reference value of jugular venous and systemic arterial saturation, during proven…
- Trial name
- POC-SctO2 (NCT05897060)
- Testing
- Venus Jugular O2 Saturation optical fiber
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Braindex
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Syncope, Presyncope
Abbott Brady 3T MRI PMCF
The objective of this post-market, clinical follow up (PMCF) study, is to confirm the long-term safety of the Tendril STS and Isoflex leads, implanted with the Assurity MRI™ or Endurity MRI™ pacemakers, in patients undergoing a…
- Conditions
- Syncope, Presyncope, Fatigue, Disorientation
- Trial name
- NCT03786640
- Testing
- 3T MRI scan
- Where
- 9 sites in Estonia, France and 3 more
- Volunteers
- 3 people
- Sponsor
- Abbott Medical Devices
Dizziness, Nausea
Efficacy of a Transcranial Vibrating System for Mitigation of Migraine Associated Vertigo
Vertigo is among the most common symptoms associated with migraine and affects 26.5% of migraine sufferers, leading to a dramatic impact in life limiting even the most simple activities.
- Conditions
- Dizziness, Nausea, Headache, Confusion
- Trial name
- NCT03886012
- Testing
- Otoband
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Otolith Labs
Delirium, Delirium Drug-Induced
Estimation of Delirium Data Completeness
Currently physicians and nurses rely on their own clinical skills and experience to diagnose and record 'delirium' in the Electronic Health Records (EHR).
- Conditions
- Delirium, Delirium Drug-Induced, Delirium Confusional State, Delirium, Cause Unknown
- Trial name
- NCT04084821
- Testing
- none - observation only
- Where
- Israel
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Efficacy Care R&D Ltd
Perceptual Disorders, Confusion
Ketamine Challenge Study With JNJ-40411813
The objective of this study is to investigate whether JNJ-40411813 versus placebo reduces psychosis-like symptoms, induced by infusion of a low dose of ketamine.
- Conditions
- Perceptual Disorders, Confusion, Schizophrenia
- Trial name
- NCT01101659
- Testing
- JNJ-40411813, normal saline, ketamine
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.